142 results on '"Heeg B"'
Search Results
2. SA15 A Systematic Review to Assess How Cure Is Modelled and Subsequently Evaluated in Health Technology Submissions to the National Institute for Health and Care Excellence (NICE)
3. HTA226 Can Prior Indirect Treatment Comparisons (ITCs) Inform Health Technology Assessment (HTA) Strategy: A Case Study in Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL)
4. PT15 Comparing the Impact of Random Forest Vs Bayesian G-Computation on Matching-Adjusted Indirect Comparisons of Treatments Between Trials: A Simulation Study
5. MSR82 Combating Sample Scarcity: A Novel Bayesian Approach to Pediatric Basket Trials
6. MSR139 Safe to Assume? Unpacking Regression Assumptions for Utility Data
7. MSR11 Evaluating the Impact of Exact Logistic Regression on Matching Adjusted Indirect Comparisons (MAICs) of Treatments Between Trials: A Simulation Study
8. HTA35 Should Health Technology Assessment (HTA) Bodies Utilize Living HTA Tools? Validation of LiveSLR® and LiveNMA™ Tools Using ICER’S Class Review in Relapsed Refractory Multiple Myeloma (RRMM)
9. MSR77 Bayesian Hierarchical Model-Based Network Meta-Analysis to Overcome Survival Extrapolation Challenges Caused by Immature Data: Application in Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) PD-L1>1%
10. HTA145 Living Network Meta-Analysis for Up-to-Date Comparative Effectiveness: A Case Study in Multiple Myeloma Maintenance
11. CO21 Validation of Crossover Adjustment Outcomes in a Randomized Clinical Trial (RCT) Using Real-World Evidence (RWE) in Non-Small Cell Lung Cancer (NSCLC)
12. P43 Navigating the Maze of Standard and Novel Population-Adjusted Indirect Comparison (PAIC) Methods
13. HTA171 Are Global Trials Good Enough to Support the Reimbursement of a New Technology in Asia? A Review of Asian HTA Submissions
14. MSR64 Utility Analysis Methods: Can One Method Fit It All or Is a Case-By-Case Approach Required?
15. P24 Improved Estimation of Overall Survival and Progression-Free Survival for State Transition Modelling in Oncology
16. MSR50 Comparing Survival Extrapolation Outcomes Using Different Network Meta-Analyses (NMA) Methods: An Application in Patients With Metastatic Renal Cell Carcinoma (MRCC) Treated With Immunotherapy (IO) Based Combinations
17. MSR134 Optimizing Fractional Polynomials by Using Variable Powers
18. MSR109 Can Jointly Modelling PFS and OS With Mixture Cure Models Overcome Data Immaturity Problems?
19. POSC313 Network Meta-Interpolation; A Fast, Novel NMA Approach Accounting for Effect Modification
20. POSC322 The Impact of Treatment Coefficient Parameterization for Mixture Cure Models on Cost-Effectiveness Models
21. P45 The Use of Historical Clinical Trial Data to Inform Survival Extrapolation
22. P44 Novel and Existing Flexible Survival Methods for Network Meta-Analyses
23. POSA428 The Impact of Treatment Effect Parameterization in Mixture Cure Models on Survival Estimates and Uncertainty
24. POSB269 The Use of External Data to Inform Survival Extrapolation in Oncology Technology Appraisals: A Comprehensive Review
25. POSA303 Influence of Treatment Effect on Parameters in Fractional Polynomials for Network Meta-Analyses
26. 1165P Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial
27. 851P Treatment efficacy for adults with relapsed or refractory acute lymphoblastic leukemia: A systematic literature review (SLR)
28. PCN113 Prevalence of MET exon 14 (METex14) Skipping in Patients with Advanced NSCLC: A Systematic Literature Review
29. 159P Clinical characteristics of patients with advanced NSCLC and MET exon 14 (METex14) skipping: A systematic literature review
30. 158P Prevalence and clinical outcomes of MET exon 14 (METex14) skipping in patients with advanced NSCLC: A systematic literature review
31. PCN28 Relationship between Surrogate Endpoints and Overall Survival in Studies That Prohibited Crossover or Reported Balanced Post-Progression Treatments; Pooled Analysis in Advanced NSCLC Patients
32. NM1 A Comparison on Different Network-Meta Analysis (NMA) Models Using Randomized Clinical Trials (RCTS) in Transplant-Ineligible (TIE) NEWLY Diagnosed Multiple Myeloma (NDMM)
33. PCV57 A Systematic Literature Review of Cost-Utility Analyses of PCSK9 Inhibitors
34. PIN52 A MODEL to Explore Clinical Outcomes with High Hepatitis B VIRUS Surface Antigen (HBSAG) Loss Rates in Chronic Hepatitis B (CHB)
35. PCN20 Can Real-World Data Replicate RCT Results? A Retrospective Comparative Effectiveness Study Of Docetaxel In Metastatic Hormone Sensitive Prostate Cancer Using German Claims Data
36. PCV9 Health IMPACT of Tafamidis in Transthyretin Amyloid Cardiomyopathy Patients: An Analysis from the Attr-ACT and the OPEN-Label Extension Studies
37. MS2 Methods to Optimise Survival Predictions Using Multistate Models in Oncology
38. RW1 Bridging The Gap Between Clinical Trials And Real World Data: Evidence On Replicability Of Efficacy Results Using German Claims Data
39. PCN13 Comparing Trial Efficacy And Real-World Effectiveness: A Retrospective Study Of Abiraterone In Metastatic Castration Resistant Prostate Cancer Using German claims
40. EX1 How to Select the Appropriate Survival Extrapolation Method? a Proposed Framework
41. PCN227 Recent Uptake Of New Agents In First-Line Treatment Of Metastatic Castration Resistant Prostate Cancer By Age Group: A Retrospective Analysis Of German Claims Data
42. PIN1 A COMPARATIVE NETWORK META-ANALYSIS OF STANDARD OF CARE TREATMENTS IN TREATMENT-NAIVE CHRONIC HEPATITIS B PATIENTS
43. PCN168 MEDICAL RESOURCE UTILIZATION (MRU) OF APALUTAMIDE (APA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) AND METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): RESULTS FROM SPARTAN AND TITAN
44. MS2 TREATMENT SWITCHING ANALYSES ON PATIENT-LEVEL DATA TO INFORM TRANSFERABILITY OF A TRIAL-BASED HEALTH ECONOMIC ANALYSIS IN METASTATIC COLORECTAL CANCER: A CASE STUDY USING PATIENT-LEVEL DATA FROM THE FIRE-3 TRIAL
45. PNS318 NETWORK META-ANALYSES COMBINING RANDOMIZED AND NON-RANDOMIZED EVIDENCE; A NICE HTA REVIEW
46. CP1 THE IMPACT OF USING AGGREGATE DATA FOR MULTISTATE MODELLING PURPOSES IN ECONOMIC EVALUATIONS
47. PCN368 ADVANCED NMA TECHNIQUES IN NICE STA SUBMISSIONS
48. ON7 TIME-TO-TREATMENT DISCONTINUATION (TTD) AS A PRAGMATIC PREDICTOR OF OVERALL SURVIVAL (OS) IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) - REAL-WORLD PERSPECTIVE
49. PNS339 BAYESIAN NETWORK META-ANALYSES WHERE INFORMATIVE PRIORS WERE USED FOR THE BETWEEN-STUDY HETEROGENEITY; A PRAGMATIC REVIEW
50. PCN62 COMPARISON OF NETWORK META-ANALYSES USING STANDARD, MIXTURE CURE AND SPLINE MODELS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.